You are here:

Valproate and pregnancy awareness survey 2019

Published on

Updated:

Valproate and pregnancy awareness survey 2019

Are you a woman or girl under the age of 55 who is taking, or has taken, sodium valproate since 1 August 2018? We want to find out how much women and girls of childbearing age know about the risks associated with the epilepsy medication, if taken during pregnancy.

For every baby exposed to sodium valproate during pregnancy, there is up to a 40 per cent risk of the baby being born with a physical or neurodevelopmental disability.

Valproate and pregnancy awareness survey 2019

We would be grateful if you could fill in our survey at the link below to help us assess:

  • how effective new regulations around prescribing the drug are;
  • whether women and girls are aware of the risks;
  • and how they feel about the pregnancy prevention programme.

Take the valproate and pregnancy survey 

New regulations

New regulations around prescribing sodium valproate (also known as Epilim, Episenta, Epival, Convulex, Depakote, Kentilim, Orlept, Syonell, Valpal and Valproic acid) were introduced by the Medicines and Healthcare products Agency in April 2018.

The survey has been launched by the three charities Epilepsy Society, Epilepsy Action and Young Epilepsy. The survey will run for four weeks until Tuesday 19 November 2019.

You should never stop taking sodium valproate without consulting your doctor.

Sodium valproate

Sodium valproate is an epilepsy drug prescribed for all seizure types including absence, myoclonus and tonic clonic seizures. New regulations have been introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) around the way in which the drug, sodium valproate is prescribed to women and girls of childbearing age. 

Campaigns

Join us to make your voice heard and help improve the lives of people with epilepsy. Through our advocacy campaigns we've spread awareness of the impact of epilepsy on people's lives and protected people with epilepsy by lobbying government.